Alzheimer Disease Clinical Trial
— QUIP IIOfficial title:
Quality Improvement PrecivityAD2(TM): A Survey and Clinical Utility Study of the PrecivityAD2 Blood Test in the Evaluation of Cognitive Impairment (QUIP II)
NCT number | NCT06025877 |
Other study ID # | C2N002 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | November 15, 2023 |
Est. completion date | October 30, 2024 |
There is a major unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and dementia. MCI impacts 12-18% of people in the United States over age 60 years (Alzheimer's Association. Mild Cognitive Impairment (MCI) available at https://www.alz.org/alzheimers-dementia/what-is-dementia/related_conditions/mild-cognitive-im pairment. Accessed August 16, 2022). MCI does not substantially interfere with daily activities, although complex functional tasks may be performed less efficiently (Knopman DS, Petersen RC. Mild cognitive impairment and mild dementia: a clinical perspective. Mayo Clin Proc. 2014;89(10):1452-1459. doi:10.1016/j.mayocp.2014.06.019). Approximately 30% of MCI patients have Alzheimer's disease (AD) as a cause of their symptoms (Lopez,OL, Kuller LH, Becker JT, et al. Incidence of dementia in mild cognitive impairment in the cardiovascular health study cognition study. Arch Neurol. 2007;64(3):416-420.doi:10.1001/archneur.64.3.416)). In contrast, dementia is defined by chronic, acquired loss of two or more cognitive abilities caused by brain disease or injury, often associated with significant interference with the ability to function at work or at usual activities. (Knopman DS, Petersen RC. Mild cognitive impairment and mild dementia: a clinical perspective. Mayo Clin Proc. 2014;89(10):1452-1459. doi:10.1016/j.mayocp.2014.06.019). Approximately 60-80% of dementia patients have AD as a cause of their symptoms (Alzheimer's Association. Mild Cognitive Impairment (MCI) available at https://www.alz.org/alzheimers-dementia/what-is-dementia/related_conditions/mild-cognitive-im pairment. Accessed August 16, 2022).
Status | Recruiting |
Enrollment | 400 |
Est. completion date | October 30, 2024 |
Est. primary completion date | June 30, 2024 |
Accepts healthy volunteers | |
Gender | All |
Age group | 55 Years and older |
Eligibility | Physician Inclusion Criteria: 1. Memory care specialists actively practicing in the United States 2. Practice serves individuals with MCI or dementia age > 55 years 3. Average patient volume > 25 visits per week (all patients seen across practice) 4. Memory care specialist with access to an online electronic survey Physician Exclusion Criteria: 1) Clinicians who practice in New York Participant Inclusion Criteria: 1. Individual with MCI or dementia 2. Age >= 55 years Participant Exclusion Criteria 1. Individual requiring test related blood draw within the state of New York 2. Participation does not seem to be in the best interest of the individual, per the ordering clinician |
Country | Name | City | State |
---|---|---|---|
United States | Josephson Wallack Munshower Neurology, P.C. | Indianapolis | Indiana |
United States | Tulane Doctors Neurosurgery Clinic | New Orleans | Louisiana |
United States | Sharlin Health and Neurology | Ozark | Missouri |
United States | Advocate Memory Center | Park Ridge | Illinois |
United States | C2N Diagnostics | Saint Louis | Missouri |
United States | UCSF Memory and Aging Center | San Francisco | California |
United States | Pacific Brain Health Center | Santa Monica | California |
Lead Sponsor | Collaborator |
---|---|
C2N Diagnostics |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in planned clinical management (Cohort A and B) | The association of the test result on medical decision making | Day 20 | |
Primary | Change in planned clinical management (Cohort B) | Evaluate the planned versus subsequent planned change in clinical management as a result of receiving the test result | Day 0 vs Day 20 | |
Primary | Difference between the actual age and symptomatology versus intended use criteria (Cohort A and B) | Evaluate the intended use criteria | Day 90 | |
Secondary | Relationship between the test result and actual clinical management (Cohort B) | Association of the test result on subsequent conducted changes in clinical management and test results when evaluating individuals with MCI or dementia in an ambulatory setting | Day 90 | |
Secondary | Change in planned clinical management compared to conducted clinical management (Cohort B only) | The evaluation of planned versus conducted change in management as a result of receiving the test result | Day 20 vs Day 90 | |
Secondary | Change in probability of AD (Cohort A and B) | Evaluate the probability of an AD Dx pre and post receipt of the test result | Day 0 vs Day 20 | |
Secondary | Change in anti-AD medication use (Cohort A and B) | Evaluate anti-AD medication use pre- and post-receipt of the test result | Day 0 vs Day 20 | |
Secondary | Change in diagnosis (Cohort B) | Evaluate any changes in diagnoses as a result of receiving the AD test result | Day 0 vs Day 90 | |
Secondary | Relationship between the test result and planned testing (Cohort B) | Evaluate the association between subsequent test ordering pre and post testing | Day 0 vs Day 20 vs Day 90 | |
Secondary | Correlations between the net promoter score and ease of use by APS2 result (Cohort B) | Focus group questions around net promoter score and ease of use, strengths, and limitations of testing | Day 90 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |